Patent Assignment
Reel/Frame 057448/0033
Assignment of Assignor's Interest
Recorded: 2021-09-09
Pages: 66
Assignor
AERPIO PHARMACEUTICALS, INC.
Executed: 2021-08-26
Assignee
EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET, SUITE A-210, WATERTOWN, MASSACHUSETTS, 02472
Covered Properties
(126)
Antibodies That Bind Human Protein Tyrosine Phosphatase Beta (Hptpbeta)
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Human Protein Tyrosine Phosphatase Inhibitors an Methods of Use
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Application:
12/558,169 →
Publication:
US 2010/0016336
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Methods for Treating Vascular Leak Syndrome
Application:
12/677,512 →
Publication:
US 2011/0268694
Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
METHOD FOR TREATING CORONARY ARTERY DISEASE USING ANTIBODY BINDING HUMAN PROTEIN TYROSINE PHOSPHATASE BETA(HPTPbeta)
Compositions and Methods for Treating Ocular Edema, Neovascularization and Related Diseases
Application:
13/253,397 →
Publication:
US 2012/0129847
Human Protein Tyrosine Phosphatase Inhibitors and Method of Use
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Application:
13/626,590 →
Publication:
US 2013/0023542
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Treatment of Ocular Disease
Methods for Treating Vascular Leak Syndrome and Cancer
Application:
13/652,203 →
Publication:
US 2013/0095065
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Methods for Treating Vascular Leak Syndrome
Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES TEHREOF
Application:
13/958,990 →
Publication:
US 2014/0044707
Methods for Treating Vascular Leak Syndrome
Application:
13/968,269 →
Publication:
US 2013/0331386
Compositions, formulations and methods for treating ocular diseases
Methods for Treating Vascular Leak Syndrome
Application:
14/075,809 →
Publication:
US 2014/0066458
Compositions and Methods for Treating Ocular Diseases
Application:
14/214,413 →
Publication:
US 2015/0050277
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells
Compositions and Methods for Treating Ocular Edema, Neovascularization and Related Diseases
Application:
14/300,385 →
Publication:
US 2014/0288134
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Treatment of Ocular Diseases
Application:
14/627,463 →
Publication:
US 2015/0232575
Hptp-Beta Inhibitors
Combination of Immunotherapies with Activators of Tie-2
VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
Application:
14/862,948 →
Publication:
US 2016/0082129
Compounds, Compositions, and Methods for Preventing Metasasis of Cancer Cells
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Patent:
46,592 →
Application:
14/938,526 →
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Compositions, Formulations and Methods for Treating Ocular Diseases
Application:
15/098,955 →
Publication:
US 2016/0220540
Compositions, Formulations and Methods for Treating Ocular Diseases
Application:
15/099,161 →
Publication:
US 2016/0220541
Methods of Treating Intraocular Pressure with Activators of Tie-2
Compositions and Methods for Treating Ocular Diseases
ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
Methods for Treating Vascular Leak Syndrome and Cancer
Methods for Treating Vascular Leak Syndrome
Application:
15/443,353 →
Publication:
US 2018/0016245
Compositions, Formulations and Methods for Treating Ocular Diseases
Application:
15/443,622 →
Publication:
US 2018/0022741
Compositions and Methods for Treating Ocular Edema, Neovascularization and Related Diseases
Application:
15/462,326 →
Publication:
US 2018/0037579
Treatment of Ocular Disease
Antibodies That Target Human Protein Tyrosine Phosphatase-Beta (Hptp-Beta) and Methods of Use Thereof to Treat Ocular Conditions
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Phosphatase Inhibitors for Treating Ocular Diseases
Application:
15/796,293 →
Publication:
US 2018/0092883
VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
Application:
15/815,097 →
Publication:
US 2018/0353614
ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
Application:
15/894,442 →
Publication:
US 2019/0023773
Compounds, Compositions, and Methods for Preventing Metasasis of Cancer Cells
Application:
15/913,392 →
Publication:
US 2019/0076405
Methods for Treating Vascular Leak Syndrome
Application:
15/930,583 →
Publication:
US 2020/0277267
Compositions, Formulations and Methods for Treating Ocular Diseases
Application:
15/958,346 →
Publication:
US 2018/0237429
Compositions, Formulations and Methods for Treating Ocular Diseases
Application:
15/958,355 →
Publication:
US 2018/0237430
Compositions, Formulations and Methods for Treating Ocular Diseases
Application:
15/958,358 →
Publication:
US 2018/0237431
Compositions, Formulations and Methods for Treating Ocular Diseases
Application:
15/969,109 →
Publication:
US 2018/0251457
Hptp-Beta Inhibitors
Methods for Treating Vascular Leak Syndrome and Cancer
Humanized Monoclonal Antibodies That Target Protein Tyrosine Phosphatase-Beta (Hptp-Beta / Ve-Ptp)
Methods of Treating Ocular Conditions by Administering Humanized Monoclonal Antibodies That Target Ve-Ptp (Hptp-Beta)
Compositions and Methods for Treating Ocular Diseases
Application:
16/257,287 →
Publication:
US 2019/0231799
Methods of Treating Diabetic Nephropathy Using Hptpb Inhibitors
Application:
16/284,349 →
Publication:
US 2019/0262321
Treatment of Ocular Disease
Application:
16/395,972 →
Publication:
US 2020/0010565
Compositions and Methods for Treating Ocular Edema, Neovascularization and Related Diseases
Application:
16/513,103 →
Publication:
US 2020/0009115
Compositions and Methods for Treating Ocular Diseases
Application:
16/559,006 →
Publication:
US 2020/0108080
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Application:
16/577,808 →
Publication:
US 2020/0253936
Multispecific Antibodies That Target Hptp-B (Ve-Ptp) and Vegf
ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
Application:
16/696,212 →
Methods for Treating Vascular Leak Syndrome
Application:
16/719,317 →
Publication:
US 2020/0207730
Treatment of Ocular Disease
Application:
16/751,824 →
Publication:
US 2020/0231703
Humanized Monoclonal Antibodies That Target Ve-Ptp (Hptp-Beta)
ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
Methods of Treating Hypertension with Activators of Tie-2
Application:
16/850,613 →
Publication:
US 2020/0352914
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
Tie-2 Activators Targeting the Schlemm's Canal
Compositions, Formulations and Methods for Treating Ocular Diseases
Application:
16/888,247 →
Publication:
US 2020/0361926
Formulations of Tie-2 Activators and Methods of Use Thereof
Methods for Treating Vascular Leak Syndrome and Cancer
Hptp-Beta Inhibitors
Application:
17/062,098 →
Publication:
US 2021/0130341
Small Molecule Activators of Tie-2
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
Application:
17/096,548 →
Publication:
US 2022/0117946
Method of Treating Ocular Conditions by Administering an Antibody That Activates TIE2 and Binds Vegf
Combinations of Tie-2 Activators and Prostaglandins and Uses Thereof
Application:
17/143,394 →
Publication:
US 2021/0212998
Methods of Treating Intraocular Pressure with Activators of Tie-2
Compositions and Methods for Treating Ocular Edema, Neovascularization and Related Diseases
Application:
17/352,698 →
Publication:
US 2022/0016086
Monoclonal antibody phosphatase inhibitors for therapeutic angiogenesis
Application:
60/790,506 →
Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
Application:
60/798,896 →
Compounds which regulate angiogenes
Application:
60/816,730 →
Compounds which regulate angiogenesis
Application:
60/816,731 →
Compounds which regulate angiogenesis
Application:
60/816,825 →
Methods for Treating Vascular Leak Syndrome
Application:
61/144,022 →
Methods for Reducing Vascular Leakage Induced by Pathogens
Application:
61/184,986 →
Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells
Application:
61/223,260 →
Compositions and Methods for Treating Ocular Edema and Neovascularization and Related Diseases
Application:
61/390,899 →
Treatment of Cancer Metastasis
Application:
61/546,697 →
Treatment of Ocular Disease
Application:
61/546,708 →
Methods for Treating Vascular Leak Syndrome
Application:
61/546,748 →
Compositions and Methods for Treating Ocular Diseases
Application:
61/792,679 →
Compositions and Methods for Treating Ocular Diseases
Application:
61/792,868 →
Compositions and Methods for Treating Ocular Diseases
Application:
61/882,048 →
Compositions and Methods for Treating Ocular Diseases
Application:
61/882,056 →
Pharmaceutical Compositions
Application:
61/934,570 →
Hptp-Beta Inhibitors
Application:
61/953,680 →
Combination of Immunotherapies with Activators of Tie-2
Application:
62/034,695 →
VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
Application:
62/054,752 →
Methods of Treating Intraocular Pressure with Activators of Tie-2
Application:
62/222,481 →
Humanized Monoclonal Antibody That Targets Ve-Ptp
Application:
62/364,381 →
Humanized Monoclonal Antibody That Targets Ve-Ptp
Application:
62/377,072 →
Methods of Treating Diabetic Nephropathy Using Hptpb Inhibitors
Application:
62/635,102 →
Bispecific Antibodies That Target Ve-Ptp (Hptp-B) and Vegf
Application:
62/735,331 →
Methods of Treating Diabetic Nephropathy Using Hptpb Inhibitors
Application:
62/790,646 →
Multispecific Antibodies That Target Hptp-B (Ve-Ptp) and Vegf
Application:
62/832,461 →
Methods of Treating Hypertension with Activators of Tie-2
Application:
62/835,626 →
Tie-2 Activators Targeting the Schlemm's Canal
Application:
62/840,068 →
Methods of Treating Pulmonary Hypertension Using Tie-2 Activators
Application:
62/840,655 →
Formulations of Tie-2 Activators and Methods of Use Thereof
Application:
62/865,653 →
Small Molecule Activators of Tie-2
Application:
62/927,233 →
Combinations of Tie-2 Activators and Prostaglandins and Uses Thereof
Application:
62/958,348 →
Formulations of Tie-2 Activators and Methods of Use Thereof
Application:
63/009,083 →
Methods of Treating Acute Respiratory Distress Syndrome with Activators of Tie-2
Application:
63/028,317 →
Combinations of Tie-2 Activators and Prostaglandins and Uses Thereof
Application:
63/089,144 →
Methods for Manufacture of Small Molecule Activators of Tie-2
Application:
63/127,411 →
Dosage Forms of Tie-2 Activators
Application:
63/127,412 →
Related Assignments
(18)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 8, 2010
From: PROCTER & GAMBLE COMPANY, THE
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 023796/0417 →
Release - Reel 023456, Frame 0052
Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY LLC
Reel/Frame 026042/0046 →
Assignment of Assignor's Interest
Nov 29, 2012
From: PETERS, KEVIN; SHALWITZ, ROBERT
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 029373/0112 →
Assignment of Assignor's Interest
Nov 29, 2012
From: AKEBIA THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 029373/0325 →
Assignment of Assignor's Interest
Jun 24, 2013
From: PETERS, KEVIN; SHALWITZ, ROBERT
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 030673/0970 →
Release of Security Interest
Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
Assignment of Assignor's Interest
May 5, 2014
From: GRAY, JEFFREY LYLE; AMARASINGHE, KANDE K. D.; CLARK, CYNTHIA MONESA; NICHOLS, RYAN MATTHEW
To: AERPIO THERAPEUTICS INC.
Reel/Frame 032822/0286 →
Assignment of Assignor's Interest
May 5, 2014
From: GRAY, JEFFREY LYLE; AMARASINGHE, KANDE K. D.; CLARK, CYNTHIA MONESA; NICHOLS, RYAN MATTHEW
To: AERPIO THERAPEUTICS INC.
Reel/Frame 032822/0143 →
Corrective Assignment to Correct the Correct Assignee's Name Previously Recorded on Reel 032822 Frame 0286. Assignor(S) Hereby Confirms the Assignment.
Jul 12, 2019
From: GRAY, JEFFREY LYLE; AMARASINGHE, KANDE K.D.; CLARK, CYNTHIA MONESA; NICHOLS, RYAN MATTHEW
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 049745/0505 →
Corrective Assignment to Correct the Correct Assignee Name Previously Recorded on Reel 032822 Frame 0143. Assignor(S) Hereby Confirms the Assignment.
Jul 12, 2019
From: GRAY, JEFFREY LYLE; AMARASINGHE, KANDE K.D.; CLARK, CYNTHIA MONESA; NICHOLS, RYAN MATTHEW
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 049745/0699 →
Change of Name
Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049918/0806 →
Change of Name
Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049924/0512 →
Change of Name
Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049924/0466 →
Change of Name
Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049922/0273 →
Change of Name
Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049920/0076 →
Change of Name
Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049919/0884 →
Change of Name
Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049919/0768 →
Assignment of Assignor's Interest
Apr 17, 2020
From: AERPIO THERAPEUTICS LLC
To: AERPIO PHARMACEUTICALS, INC.
Reel/Frame 052432/0789 →